Patients have typically been told to take aspirin and an oral anticoagulant following treatment to help combat the risk of blood clots. Now, they can skip the aspirin altogether.

An exclusivity agreement is stopping Liquidia Corporation from gaining full FDA approval of its new inhalation powder for pulmonary arterial hypertension. The company said it is disappointed with the agency's decision and plans to "take quick action."

Ron Blankstein, MD, explains how and why Medicare is proposing an increase to hospital payments for coronary CT angiography.

Cath labs, like radiology suites and operating rooms, are leading contributors to the world’s growing carbon footprint.

Apixaban, empagliflozin, rivaroxaban and sacubitril/valsartan are just some of the medications included in this initial round of Medicare price negotiations. Their new prices were reduced by 56%, 66%, 62% and 53%, respectively. 

The FDA warned that the devices failed a safety inspection, but were still distributed for patient use. They have now all been located. 

The management of stable angina has been evolving at a rapid rate. Using a one-size-fits-all strategy is becoming a thing of the past, replaced by a patient-centered approach that requires open communication and a healthy understanding of recent clinical research.

A software update for the pump's mobile app was expected to fix ongoing battery issues, but the problem remains.